Table 3 Univariate and multivariate analysis of the complication-free survival of patients with HBV-related cirrhosis undergoing splenectomy for hypersplenism and portal hypertension

Antiviral therapy

0.074

7.229 (1.271–41.117)

0.026

 Yes

28

82.6

64.8

64.8

 No

29

88.0

50.1

25.0

Gender

0.717

1.023 (0.252–4.159)

0.974

 Men

44

80.6

61.3

43.6

 Women

13

100.0

55.6

55.6

Age (years)

0.004

9.264 (1.806–47.528)

0.008

 ≤ 40

26

95.8

78.8

63.0

 > 40

31

75.0

37.5

37.5

Child–Pugh grade

0.968

7.848 (0.776–79.315)

0.081

 A

19

81.2

54.1

54.1

 B and C

38

87.6

57.1

47.6

WBC (×10⁹/L)

0.485

5.505 (0.791–38.301)

0.085

 ≥ 3

20

94.1

65.9

32.9

 < 3

37

80.6

51.6

43.0

Platelet (×10⁹/L)

0.904

0.307 (0.033–2.834)

0.298

 ≥ 50

13

100.0

71.4

35.7

 < 50

44

82.1

52.8

44.0

ALT (IU/L)

0.973

1.959 (0.392–9.794)

0.413

 < 40

28

91.7

62.7

62.7

 ≥ 40

29

79.1

47.5

28.5

AST (IU/L)

0.927

0.791 (0.168–3.726)

0.766

 < 40

27

86.3

50.8

50.8

 ≥ 40

30

84.6

61.1

40.7

Serum bilirubin (μmol/L)

0.468

1.698 (0.120–24.005)

0.695

 < 40

49

85.3

53.3

40.0

 ≥ 40

8

85.8

85.8

85.8

Serum albumin (g/L)

0.688

1.418 (0.276–7.292)

0.676

 ≥ 32

41

86.11

54.2

38.7

 < 32

16

83.3

62.5

62.5

INR

0.516

0.372 (0.043–3.228)

0.369

 < 1.2

25

100.0

57.1

57.1

 ≥ 1.2

32

100.0

71.4

51.0

HBeAg

0.408

0.573 (0.122–2.696)

0.481

 Positive

22

80.0

47.0

31.0

 Negative

35

89.2

64.4

51.5

HBV DNA (IU/ml)

0.471

1.599 (0.405–6.308)

0.503

 < 10⁴

26

81.8

58.4

43.8

 ≥ 10⁴

31

88.4

53.7

40.3